CareDx to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on March 22, 2018
March 06 2018 - 8:00AM
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company
focused on the discovery, development and commercialization of
clinically differentiated, high-value diagnostic solutions for
transplant patients, today announced that it will release financial
results for the fourth quarter and fiscal year 2017 after the
market closes on Thursday, March 22, 2018. Peter Maag, Chief
Executive Officer, and Michael Bell, Chief Financial Officer, will
host a conference call to review the Company’s results beginning at
1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may
do so by dialing 1-877-705-6003 for domestic callers or
1-201-493-6725 for international callers. Please reference
Conference ID: 13677210. To listen to a live webcast, please
visit the investor relations section of CareDx’s website at:
www.CareDx.com.
A replay of the call will be available beginning March 22, 2018
at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on April 5,
2018. To access the replay, dial 1-844-512-2921 or
1-412-317-6671 and reference Conference ID: 13677210. The
webcast will also be available on CareDx’s website for one year
following the completion of the call.
About CareDx CareDx,
Inc., headquartered in Brisbane, California, is a molecular
diagnostics company focused on the discovery, development and
commercialization of clinically differentiated, high-value
diagnostic solutions for transplant recipients. CareDx offers
products across the transplant testing continuum, including
AlloMap® and AlloSure™ for post-transplant surveillance and Olerup
SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA
testing.
For more information, please visit: www.CareDx.com.
CONTACT:
Investor RelationsDavid ClairIntegrated Corporate Relations,
Inc.646-277-1266david.clair@icrinc.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024